Merak-Dubhe Therapeutics Overview
- Year Founded
-
2026
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$931K
- Investors
-
2
Merak-Dubhe Therapeutics General Information
Description
Provider of therapeutics intended to improve the treatment of inflammatory bowel diseases through precision medicine. The company offers a proprietary biomarker platform, gut-selective oral small-molecule therapeutics, and patient-derived multi-omics analysis, enabling healthcare providers and patients with inflammatory bowel diseases to access targeted treatments with localized efficacy while reducing systemic immunosuppression.
Contact Information
Website
www.mdtx.co.jpCorporate Office
- Room 5N5, Clinical Research Promotion Center, Tohoku University Hospital
- 1-1 Seiryo-cho, Aoba-ku
- Sendai, 980-8574
- Japan
Corporate Office
- Room 5N5, Clinical Research Promotion Center, Tohoku University Hospital
- 1-1 Seiryo-cho, Aoba-ku
- Sendai, 980-8574
- Japan
Merak-Dubhe Therapeutics Timeline
Merak-Dubhe Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Seed Round | 06-Jul-2026 | $931K | Completed | Startup | ||
| 1. University Spin-Out | 16-Apr-2026 | Completed | Startup |
Merak-Dubhe Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Pre-Seed Preferred |
Merak-Dubhe Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Merak-Dubhe Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Merak-Dubhe Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| TOHOKU University Venture Partners | Venture Capital | Minority | ||
| Tohoku University | University |
Merak-Dubhe Therapeutics FAQs
-
When was Merak-Dubhe Therapeutics founded?
Merak-Dubhe Therapeutics was founded in 2026.
-
Where is Merak-Dubhe Therapeutics headquartered?
Merak-Dubhe Therapeutics is headquartered in Sendai, Japan.
-
What is the size of Merak-Dubhe Therapeutics?
Merak-Dubhe Therapeutics has 2 total employees.
-
What industry is Merak-Dubhe Therapeutics in?
Merak-Dubhe Therapeutics’s primary industry is Drug Discovery.
-
Is Merak-Dubhe Therapeutics a private or public company?
Merak-Dubhe Therapeutics is a Private company.
-
What is the current valuation of Merak-Dubhe Therapeutics?
The current valuation of Merak-Dubhe Therapeutics is .
-
What is Merak-Dubhe Therapeutics’s current revenue?
The current revenue for Merak-Dubhe Therapeutics is .
-
How much funding has Merak-Dubhe Therapeutics raised over time?
Merak-Dubhe Therapeutics has raised $931K.
-
Who are Merak-Dubhe Therapeutics’s investors?
TOHOKU University Venture Partners and Tohoku University have invested in Merak-Dubhe Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
